Elanco Animal Health Incorporated $ELAN Shares Bought by Capital World Investors

Capital World Investors raised its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,078,888 shares of the company’s stock after acquiring an additional 78,888 shares during the quarter. Capital World Investors’ holdings in Elanco Animal Health were worth $41,869,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Hsbc Holdings PLC lifted its stake in Elanco Animal Health by 434.2% in the 2nd quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after buying an additional 102,686 shares in the last quarter. Norges Bank purchased a new stake in Elanco Animal Health during the 2nd quarter worth approximately $12,502,000. Amalgamated Bank raised its holdings in shares of Elanco Animal Health by 793.7% during the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock valued at $4,563,000 after acquiring an additional 201,226 shares during the last quarter. Independent Advisor Alliance raised its holdings in shares of Elanco Animal Health by 364.5% during the third quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock valued at $1,974,000 after acquiring an additional 76,920 shares during the last quarter. Finally, State of Michigan Retirement System purchased a new position in shares of Elanco Animal Health in the third quarter valued at approximately $2,383,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $22.64 on Friday. The stock has a fifty day simple moving average of $24.51 and a 200-day simple moving average of $22.15. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The stock has a market cap of $11.26 billion, a PE ratio of -47.17, a P/E/G ratio of 2.99 and a beta of 1.83. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm earned $0.14 EPS. Elanco Animal Health’s revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on ELAN. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.67.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.